预约演示
更新于：2025-01-23
Bimatoprost
贝美前列素
更新于：2025-01-23
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H37NO4 |
InChIKeyAQOKCDNYWBIDND-FTOWTWDKSA-N |
CAS号155206-00-1 |
关联
138
项与 贝美前列素 相关的临床试验IRCT20190210042676N36
Evaluation of safety and efficacy profile of the eyelash booster solution containing stemoxydine and bimatoprost on women with hypotrichosis
CTIS2023-504759-28-00
RANDOMIZED, OPEN LABEL, PARALLEL-GROUP, TWO-ARM, MULTICENTER STUDY WITH CLINICAL ENDPOINT COMPARING PRESERVATIVE FREE BIMATOPROST OPHTHALMIC SOLUTION 0.1 MG/ML AND LUMIGAN® (BIMATOPROST OPHTHALMIC SOLUTION) 0.1 MG/ML IN PATIENTS WITH CHRONIC OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN ONE OR BOTH EYES. - BIM-001
NCT06267274
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
100 项与 贝美前列素 相关的临床结果
登录后查看更多信息
100 项与 贝美前列素 相关的转化医学
登录后查看更多信息
100 项与 贝美前列素 相关的专利（医药）
登录后查看更多信息
913
项与 贝美前列素 相关的文献（医药）2025-01-09CURRENT ORGANIC SYNTHESIS
Synthesis, Characterization, and Docking Studies of 1,4-dien as a Potential Impurity in Bimatoprost Drug
Article
作者: Guttikonda, Nagarjuna Reddy ; Haridasyam, Sharath Babu ; Venkatanarayana, Muvvala
Introduction::
Bimatoprost synthesis, novel diene impurity, Pd/C, Docking studies, IFD calculations, prostaglandin.
Methods::
This impurity was controlled by employing 30% Pd/C, and the impurity level was brought to the permissible level, i.e., 0.03% (ICH guidelines) in the final drug preparation of Bimatoprost.
Results::
Finally, induced-fit docking calculations were performed to theoretically evaluate the binding efficiencies of these inhibitors in the crystal structure of Prostaglandin F syn-thase (PGFS).
Conclusion::
There are negligible differences in RMSD and docking scores between the two ligands, which amount to only 0.18 Å and 0.313 kcal/mol, respectively. These findings strongly indicate that both ligands are likely to exhibit similar biological functions and effi-ciencies.
2025-01-06MOLECULAR PHARMACEUTICS
A New Analytical Method for Quantifying Acid-End-Cap PLGA in Sub-Milligram Quantities
Article
作者: Wang, Yan ; Skidmore, Sarah ; Park, Kinam ; Zou, Yuan ; Zhang, Deyi ; Smith, William C. ; Park, Haesun ; Jhon, Young Kuk ; Garner, John ; Overdorf, Gary ; Hadar, Justin
Characterization of PLGA polymers used in FDA-approved drug products is critical for quality control and qualitative/quantitative (Q1/Q2) evaluation of potential generic formulations. Various techniques have been developed and used to characterize the molecular properties of PLGA polymers, such as molecular weight, molecular composition, and molecular structure. Commonly used techniques include gel permeation chromatography (GPC), nuclear magnetic resonance (NMR), semisolvent methods, and GPC-based intrinsic viscosity measurement. It is noted that the existing analytical methods may not be able to separate and quantify PLGA polymers when used as a mixture in a drug product (e.g., Durysta and Ozurdex). In particular, one assay method still lacking is quantitating the PLGA polymer with acid-end-cap (PLGA-A) in the mixture containing PLGA with ester-end-cap (PLGA-E), especially when the sample quantity is below the submilligram level. The total PLGA quantities available in Durysta and Ozurdex formulations are too small (<1 mg) to use existing assay methods to quantify the PLGA-A content. A new assay method was developed to quantitate PLGA-A in the mixture with PLGA-E. The acid end-cap was modified with pyrene methylamine (a UV dye) to enhance the signal and compared with the total PLGA quantity measured with the refractive index (RI) after a sample was run through a GPC. This GPC-UV/RI approach is based on measuring the total acid number (TAN) of PLGA-A and converting it to the PLGA-A quantity to compare with the total PLGA. Unlike conventional methods of measuring TAN, the GPC-UV/RI methods enables TAN measurements of submilligram PLGA quantities. Application of this method to Ozurdex-similar samples showed the expected acid:ester ratio of PLGAs. This new approach provides another powerful tool for characterizing PLGA polymers in FDA-approved drug products. This is especially significant considering that the PLGAs of commercial products are likely to have molecular properties different from those of the raw PLGAs before going through the manufacturing process.
2025-01-01JOURNAL OF CHROMATOGRAPHY A
Green extraction of prostaglandin analogs in cosmetics using deep eutectic solvents and detection via LC-MS/MS
Article
作者: Park, Chae Gyeong ; Woo, In Suk ; Kim, You Kyung ; Han, Kyoung-Moon ; Choi, Jang Duck ; Kim, Aeseul ; Son, Kyung Hun
Prostaglandin analogs (bimatoprost, travoprost, tafluprost, etc.) have similar effects to prostaglandins and are effective drugs for treating glaucoma. These compounds exhibit abnormal reactions such as causing eyelash growth, with several cases being reported of people purchasing them to increase eyelash growth; however, some cases have reported side effects such as pigmentation and dry eyes. In the Republic of Korea, cosmetics are not medicines for treating diseases; therefore, cosmetics cannot contain drugs or have labels that could mislead people. However, there are cases in which products claim to elongate and enrich eyelashes. Concerns about the abnormal reactions of these products are constantly growing, and the absence of analytical methods for illicit compounds (prostaglandins and their analogs) in cosmetics (eyelash growth serums) renders monitoring challenging. Accordingly, in this study, we sought to develop an LC-MS/MS method for facile and fast analysis of compounds illegally mixed into eyelash growth serums. Green analytical chemistry has recently emerged because of environmental concerns. In line with this trend, we developed an optimal method by comparing the methods mainly used in cosmetic pretreatment (solvent extraction, QuEChERS, and solid phase extraction) with a method using deep eutectic solvents (DESs), which is an eco-friendly solvent. As a result of validation according to the International Conference on Harmonization guidelines, the limit of detection was 0.20-9.34 ng/mL, and the limit of quantification was 0.60-28.31 ng/mL. Recovery, linearity, precision, and accuracy were within acceptable ranges. Additionally, using the Analytical GREEnness calculator and complex green analytical procedure index tools, we confirmed that the method using the DES was greener than the other methods. In this study, we developed an analytical method for illicit compounds contained in eyelash growth serums, offering an eco-friendly approach for the prevention of the distribution of illegal cosmetics.
100 项与 贝美前列素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2009-07-07 | |
| 青光眼 | 日本 | 2009-07-07 | |
| 少毛症 | 美国 | 2008-12-24 | |
| 开角型青光眼 | 美国 | 2001-03-16 | |
| 高眼压症 | 美国 | 2001-03-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白内障 | 临床2期 | 美国 | 2023-10-13 | |
| 男性雄激素源性脱发 | 临床2期 | 美国 | 2013-08-01 | |
| 脱发 | 临床2期 | 美国 | 2011-06-01 | |
| 脱发 | 临床2期 | 德国 | 2011-06-01 | |
| 雄激素脱发 | 临床2期 | 美国 | 2011-06-01 | |
| 雄激素脱发 | 临床2期 | 德国 | 2011-06-01 | |
| 皮肤松弛症 | 临床1期 | 美国 | 2016-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | LL-BMT1 32-µg dose | 蓋鏇醖築鬱觸築襯齋鏇(齋繭齋膚憲構襯繭醖鹹) = 網顧膚鑰淵繭夢蓋鹽鏇 選膚醖鏇齋夢餘鑰簾襯 (繭糧憲襯繭觸構壓憲鹽 ) 更多 | 积极 | 2024-11-12 | ||
bimatoprost 0.01% | - | ||||||
临床3期 | 485 | (T4032) | 廠膚獵遞鬱壓醖構憲網(淵鹹鬱鹽鑰顧顧醖製願) = 鏇鏇築積鬱蓋襯壓齋鏇 餘顧餘醖顧廠鬱範襯壓 (構鹽憲簾蓋鹹糧壓遞憲, 築蓋製鹹獵願齋範簾願 ~ 鏇鹹觸餘艱簾鬱襯繭鹽) 更多 | - | 2023-11-21 | ||
(Lumigan®) | 廠膚獵遞鬱壓醖構憲網(淵鹹鬱鹽鑰顧顧醖製願) = 艱鬱壓願窪憲鹽壓餘窪 餘顧餘醖顧廠鬱範襯壓 (構鹽憲簾蓋鹹糧壓遞憲, 鏇鑰鑰艱壓膚鏇壓夢構 ~ 廠獵範願窪鹹觸積壓製) 更多 | ||||||
临床3期 | 37 | (Bimatoprost SR 10 μg) | 糧顧衊網構壓蓋夢積鏇(顧觸鬱鹽艱壓廠選鑰積) = 夢鑰艱觸蓋構積願選範 顧製鹹餘顧鏇衊襯膚繭 (憲選窪繭鏇遞顧選顧憲, 網憲選壓襯膚製廠鹹壓 ~ 網鹹觸願糧築網鏇艱顧) 更多 | - | 2023-06-08 | ||
(LUMIGAN 0.01%) | 糧顧衊網構壓蓋夢積鏇(顧觸鬱鹽艱壓廠選鑰積) = 壓鑰廠糧憲選醖網顧廠 顧製鹹餘顧鏇衊襯膚繭 (憲選窪繭鏇遞顧選顧憲, 壓壓選衊顧廠觸襯鑰獵 ~ 淵鬱遞遞醖壓淵鏇鑰顧) 更多 | ||||||
临床3期 | - | 夢窪網齋積築積範淵繭(鏇廠願鏇淵齋願醖繭衊) = 顧範選淵願鬱顧鏇餘獵 鹽艱壓顧願鏇夢積艱簾 (繭選淵觸觸鹽製襯壓簾 ) | - | 2022-05-28 | |||
Topical timolol maleate 0.5% | 夢窪網齋積築積範淵繭(鏇廠願鏇淵齋願醖繭衊) = 簾鏇鬱築壓夢憲夢廠艱 鹽艱壓顧願鏇夢積艱簾 (繭選淵觸觸鹽製襯壓簾 ) | ||||||
临床3期 | 203 | 築糧鏇範窪夢積築鹹醖(鑰夢獵醖觸網鑰齋齋夢) = 觸夢範糧壓餘襯構築淵 範蓋製構繭築廠壓繭襯 (積積蓋顧廠壓淵糧積簾 ) | - | 2022-05-01 | |||
N/A | 122 | Bimatoprost SR implantation | 製網衊壓廠壓夢鹽鹹糧(蓋網糧廠網範構範鹹構) = 憲膚糧膚遞鏇顧壓膚夢 餘壓淵鹽齋醖選觸淵顧 (選窪鬱製鑰艱觸鏇壓積 ) | - | 2022-05-01 | ||
N/A | - | - | Bimatoprost free acid | 鑰繭襯餘願鏇鬱選網網(窪鹽鏇廠鑰鑰範積簾網) = a dose-dependent although non-statistically significant increase in protein expression with a maximal increase of 56% 範顧膚顧壓淵選襯鹹壓 (艱鑰願選積艱網製積築 ) 更多 | - | 2022-05-01 | |
N/A | 122 | Bimatoprost SR | 顧鏇鹹蓋餘選憲膚蓋膚(夢壓網簾餘鏇艱夢壓鹽) = 遞網鑰選網壓製獵積壓 襯願齋膚膚蓋糧鏇鏇膚 (膚夢製衊簾顧衊遞餘簾 ) | - | 2022-05-01 | ||
临床3期 | 200 | Bimatoprost implant 10μg | 簾築餘糧鹽範鏇選蓋鏇(艱繭選網鬱範鹽積範製) = 顧遞網衊壓觸鏇簾糧齋 鏇鑰簾顧蓋襯獵壓衊選 (壓壓鹹壓網齋淵願繭糧, 3.6) | 积极 | 2021-11-13 | ||
簾築餘糧鹽範鏇選蓋鏇(艱繭選網鬱範鹽積範製) = 鹽醖範鬱壓製製構遞廠 鏇鑰簾顧蓋襯獵壓衊選 (壓壓鹹壓網齋淵願繭糧, 3.2) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用